Media News

U.S. FDA Approves Clinical Trial Application for IASO Bio’s BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 22, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products,, today announced that the Investigational New Drug (IND) application for its in-house developed BCMA CAR-T CT103A (equecabtagene autoleucel) has been...

New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH® CTC count in patients with metastatic breast cancer

Integration of CTC (Circulating Tumor Cell) enumeration* to decide between endocrine therapy and chemotherapy may lead to improved clinical outcomes and quality of life for patients with oestrogen receptor (ER) positive)/human epidermal growth factor receptor (HER) 2 negative metastatic breast cancer (MBC). BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2022 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of...

Gemini Rosemont adds Peninsula Life Science Center eight-story office building to portfolio in all cash transaction

LOS ANGELES, Dec. 22, 2022 /PRNewswire/ -- Gemini Rosemont Commercial Real Estate, a vertically integrated real estate investment management firm specializing in Class A multi-tenant office and luxury residential properties, has acquired Peninsula Life Science Center for $59,350,000. Gemini Rosemont adds Peninsula Life Science Center eight-story office building to West...

Everest Medicines’ Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received acceptance from the U.S. Food and Drug Administration (FDA) for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA's decision is expected in the second half of...

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) in February 2023 Telix pipeline featured across seven presentations including first reveal of the...

Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will be presenting at the Biotech Showcase during JPM week, taking place in San Francisco, CA, USA from January 9 to 11, 2023. Nuevocor will also be giving an oral presentation on new pre-clinical data for its LMNA cardiac gene therapy...

Waterdrop Chief Actuary Hui Teng: Good Products and Services Are the Underlying Logic of High-quality Transformation for Health Insurance

BEIJING, Dec. 21, 2022 /PRNewswire/ -- At the recently held 2022 China Insurance and Aged Healthcare Forum, Hui Teng, Chief Actuary of Waterdrop Inc., was invited to give a speech titled Good Products and Services Are the Underlying Logic of High-quality Transformation for Health Insurance. He shared Waterdrop's innovative practice in the high-quality transformation of health insurance products...

CGTN: ‘New Approaches’: How China stepped up its COVID-19 treatments

BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helped China evade deadlier variants than Omicron and prevented many deaths, the development of effective COVID-19 treatments also...

I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

PALO ALTO, Calif., Dec. 21, 2022 /PRNewswire/ -- I Peace, Inc. (https://www.ipeace.com), has been awarded a "Special Recognition in Cell Therapy" during BioSpectrum Asia Excellence Award 2022 ceremony held in Singapore on December 2 (https://www.biospectrumasia.com/news/115/21473/biospectrum-asia-announces-editors-choice-award-winners-for-2022.html). I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced...

Medidata awarded International Innovation Award for Medidata Sensor Cloud

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- For the third consecutive year, Medidata, a Dassault Systèmes company, was awarded the International Innovation Award. This year, the Medidata Sensor Cloud won the award under the Service and Solution category. Sensor Cloud provides cutting-edge data ingestion capabilities focused on transforming the clinical trial experience for...